Comparing immunotherapy re-challenge plus chemoradiotherapy versus chemoradiotherapy alone in metastatic esophageal squamous cell carcinoma after first-line immunotherapy failure.

Discov Oncol · 2026 · PMC13319282 · PMID 42096133

Europe PMC DOI

hedged sentence

0.1940

closest p · 3.9× alpha

0.1940

boldest claim

The sentences

a favorable trendP = 0.194not close (p > 0.1)

The median PFS of the IO + CRT group was 6.8 months (95% CI : 5.0-10.3), showing a favorable trend (HR = 0.69; 95% CI : 0.40–1.21; P = 0.194), compared with the PFS of 3.9 months (95% CI : 2.5–7.9) in the CRT group.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.